Imperial Innovations Group plc portfolio company IXICO Limited, is to be acquired by Phytopharm plc in a proposed reverse takeover. The enlarged Phytopharm group, to be renamed IXICO plc, will benefit from a strengthened balance sheet to grow its clinical trial services business and to bring new technology solutions to the diagnosis of dementia and other conditions. The newly-quoted IXICO plc will use the new ticker 'IXI'.

Maina Bhaman, Director of Healthcare Ventures at Innovations, will be joining the IXICO plc board on completion.